Melanoma
From the Journals
Sharp declines for lung cancer, melanoma deaths fuel record drop in cancer mortality
Reductions in smoking are largely responsible for the lung cancer progress, while immunotherapy and targeted treatments have improved survival in...
From the Journals
New toxicity subscale measures QOL in cancer patients on checkpoint inhibitors
With further validation, the instrument could become an important tool for evaluation of treatment-related toxicity.
Conference Coverage
Combo elicits lasting responses in metastatic melanoma
NATIONAL HARBOR, MD. – In a phase 1/2 trial of previously untreated advanced melanoma patients, the combination of bempegaldesleukin and nivolumab...
From the Journals
Melanoma incidence drops in younger age groups
Fewer teens and young adults developed melanoma between 2006 and 2015, while incidence increased in older adults.
Conference Coverage
TLR9 agonist may overcome resistance to anti–PD-1 therapy in melanoma
NATIONAL HARBOR, MD. – CMP-001 plus pembrolizumab produced durable responses in patients who had progressed on prior...
Conference Coverage
In Oregon, ‘war on melanoma’ takes flight
LAS VEGAS – Research project hopes to shrink melanoma mortality by emphasizing education, screening.
Conference Coverage
Melanoma incidence continues to increase, yet mortality stabilizing
LAS VEGAS –Targeted screening efforts that stratify by risk factors and by age “makes screening more efficient and more cost effective.”
From the Journals
Case-control study IDs several novel risk factors of post-HCT melanoma
Latest News
Levothyroxine dose for checkpoint inhibitor toxicity may be too high
CHICAGO – Dosing need not be automatically boosted when starting checkpoint inhibitor therapy.
From the Journals
MMS linked with better survival in early-stage melanoma
Patients who underwent Mohs micrographic surgery had moderately better survival, compared with those who were treated with wide margin excision....
From the Journals
Nivolumab-ipilimumab nets long-term survival in advanced melanoma
An update of CheckMate 067 finds that with combination nivolumab and ipilimumab therapy, 52% of patients were alive at 5 years, and the large...